Syndrome of lipodystrophy, hyperlipidemia, insulin resistance, and diabetes in treated patients with human immunodeficiency virus infection

Endocrine Practice

Volumn 7, Issue 6, 2001, Pages 430-437

  Graber, A L ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTILIPEMIC AGENT; ATORVASTATIN; ATOVAQUONE; CLARITHROMYCIN; DIDANOSINE; FENOFIBRATE; FOLINIC ACID; GEMFIBROZIL; GLIBENCLAMIDE; HYDROXYUREA; INDINAVIR; INSULIN; INSULIN LISPRO; INSULIN ZINC SUSPENSION; INTERLEUKIN 2; LAMIVUDINE; METFORMIN; NELFINAVIR; PENTAMIDINE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TRIACYLGLYCEROL; TRIMETREXATE; ZIDOVUDINE;

ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BUTTOCK; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FACE; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LABORATORY TEST; LEG; LIPOATROPHIC DIABETES MELLITUS; LIPODYSTROPHY; MALE; METABOLIC DISORDER; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PHYSICAL EXAMINATION; PNEUMOCYSTOSIS;

EID: 0035196046     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.7.6.430     Document Type: Article

References (29)

1. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: The Swiss HIV Cohort Study
2. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
3. "Buffalo hump" in men with HIV-1 infection
4. Fat distribution and metabolic changes in patients with HIV infection
5. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
6. HIV protease inhibitor-related lipodystrophy syndrome
7. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
8. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
9. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: Preliminary results of the LIPOCO study
10. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
11. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
12. Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
13. Insulin-induced lipoatrophy: Evidence for an immune pathogenesis
14. Human insulin-induced lipoatrophy: Successful treatment using a jet-injection device [erratum in Diabetes Care. 1997;20:119]
15. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
16. Lipodystrophy and hepatomegaly with diabetes, lipemia and other metabolic disturbances
17. Lipoatrophic diabetes
18. LMNA R482Q mutation in partial lipodystrophy associated with reduced plasma leptin concentration
19. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy
20. The perils of portliness: Causes and consequences of visceral adiposity
21. Surgical removal of visceral fat reverses hepatic insulin resistance
22. HIV-protease inhibitors
23. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
24. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
25. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
26. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
27. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
28. Effect of troglitazone on body fat distribution in type 2 diabetic patients
29. Use of fenofibrate in the management of protease inhibitor-associated lipid abnormalities